Aktie 300254 SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen ShanXi C&Y Pharmaceutical Group Co.,LTD.

Aktien

300254

CNE1000016D0

300254

Schlusskurs Shenzhen S.E.
Andere Börsenplätze
 00:00:00 15.05.2024 		% 5 Tage % 1. Jan.
9,29 CNY -1,90 % Intraday Chart für ShanXi C&Y Pharmaceutical Group Co.,LTD. -8,20 % -3,53 %
12.04. ShanXi C&Y Pharmaceutical Group Co.,LTD. meldet Ergebnis für das erste Quartal zum 31. März 2024 CI
18.03. ShanXi C&Y Pharmaceutical Group Co., Ltd. meldet Ergebnis für das Geschäftsjahr bis zum 31. Dezember 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024
ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 184.999997 million in funding
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. announced that it expects to receive CNY 105 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.
C&Y Pharmaceutical Raises $15.5 Million in Private Placement
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it has received CNY 109.999995 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 130 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors
ShanXi C&Y Pharmaceutical Group Co., Ltd. and Chen Jinsong entered into an equity transfer agreement to acquire 15.43% stake in Sichuan C&Y Traditional Chinese Medicine Co., Ltd. from Chen Renhu and Tang Wenjing.
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
Hangzhou Pollen Group Company Limited announced that it has received CNY 115 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 300254 Aktie
  4. Nachrichten ShanXi C&Y Pharmaceutical Group Co.,LTD.
  5. Andere Sprachen